The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency’s work affects Americans’ health and safety.

Guests

  • Marc Kaufman Reporter on the national desk of "The Washington Post"
  • Dr. Jerry Avorn Author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
  • Alan Goldhammer, PhD Associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Sen. Charles Grassley (R-Iowa), ranking member of the Senate Finance Committee
  • Dr. Sandra Kweder Deputy director of the FDA's Office of New Drugs

Related Links

Topics + Tags

Most Recent Shows

A Push To Improve America’s Nursing Homes

Thursday, Sep 28 2023The Biden administration has released a proposal  to raise standards in nursing homes. Why one expert calls it the most significant development for the industry in decades -- and why it might still not be enough.